HotPennyStockNews.com is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
Los Angelas, CA -- (SBWIRE) -- 10/08/2012 -- Abbott Laboratories (ABT) is engaged in the discovery, development, manufacture, and sale of a range of health care products. Abbott operates in five segments: Proprietary Pharmaceutical Products, Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Abbott Laboratories (NYSE: ABT) had its neutral rating reaffirmed by analysts at JPMorgan Chase. The firm currently has a $73.00 price target on the stock. Abbott Laboratories (NYSE: ABT) is -0.3108 - -0.43% from the previous close of $71.61. It traded between $70.85 - 71.56 with total traded volume of 1369796 shares. Keep a close eye on ABT, as the stock has been showing unusual moves over the past weeks. At Current market price, ABT has recovered +38.36% from its 52-week Low of 51.53 and has Pulled back -0.85% from its 52-week high of 71.91.
Can ABT Continue To Move Higher? Find Out Here
Achillion Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. The Company is engaged in the development of antivirals for the treatment of chronic hepatitis C infection (HCV), and the development of antibacterials for the treatment of resistant bacterial infections. The Company focuses on the development of four drug candidates for the treatment of HCV: ACH-1625, a NS3 protease inhibitor for the treatment of HCV, which is being tested in a phase IIa clinical trial, ACH-2684, a NS3 protease inhibitor for the treatment of HCV, which is being tested in a phase I clinical trial; ACH-2928, a NS5A inhibitor for the treatment of HCV, which is being tested in a phase I clinical trial, and ACH-3102, a NS5A inhibitor for the treatment of HCV, which is being prepared for investigational new drug (IND), filing and initiation of a phase I clinical trial.Achillion Pharmac (NasdaqNM:ACHN) are trading at $10.77 and is +30.11% from its 50-day Moving Average price of $8.2777 and +43.34% from its 200-day Moving Average price of $7.5134. The average trading volume is 1212950 shares and its market capitalization is $781.2M.Achillion Pharmaceuticals, Inc.(NASDAQ:ACHN) shares climbed 2.78% and closed at $11.10 in the previous trading session. The company, on Sept. 27, said it achieved positive proof-of-concept results for its hepatitis C drug, allowing it to move forward with its clinical trials of the drug. The company received fast-track designation from the U.S. Food and Drug Administration in May.
Can ACHN Continue to Rise? Find Out Here
Aetna Inc. (AET) is a diversified healthcare benefits company. The Company offers a range of traditional and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioral health, group life and disability plans, medical management capabilities, Medicaid healthcare management services and health information exchange technology services. The Company’s operations are conducted in three business segments: Health Care, Group Insurance and Large Case Pensions. Its customers include employer groups, individuals, college students, part-time and hourly workers, health plans, healthcare providers, governmental units, government-sponsored plans, labor groups and expatriates.New York, NY- Aetna Inc. Common (NYSE:AET) is very active today and traded between $41.40 - 42.34 with total traded volume of 2676052 shares. At a current price of 42.09, AET is +0.43 - +1.03% from the previous close of $41.66. Moreover, At Current Market Price, AET is in the distance of +7.11% from its 50-day Moving Average price of $39.2977 and +1.96% from its 200-day Moving Average price of $41.2795.
Should A Trader Buy Or Sell AET Now? CHECK HERE
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) are a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors (GPCRs), in four therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena Pharmaceutic (NasdaqNM: ARNA) is -0.045 - -0.52% from the previous close of $8.635. It traded between $8.41 - 8.78 with total traded volume of 2793981 shares. Keep a close eye on ARNA, as the stock has been showing unusual moves over the past weeks. At Current market price, ARNA has recovered +576.38% from its 52-week Low of 1.27 and has Pulled back -36.37% from its 52-week high of 13.50.Arena Pharmaceuticals (ARNA) still suffers from an underperform rating from Credit Suisse and other analysts.
How Should Investors React To ARNA Now? To know Free sign up here
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)